



## Guideline Summary NGC-10399

### Guideline Title

**Screening and management of lipids.**

### Bibliographic Source(s)

University of Michigan Health System. Screening and management of lipids. Ann Arbor (MI): University of Michigan Health System; 2014 May. 20 p. [20 references]

### Guideline Status

This is the current release of the guideline.

The guideline updates a previous version: University of Michigan Health System. Screening and management of lipids. Ann Arbor (MI): University of Michigan Health System; 2009 Feb. 15 p. [12 references]

### Scope

#### Disease/Condition(s)

Atherosclerotic cardiovascular disease (ASCVD) including:

- Stroke
- Peripheral arterial disease (PAD)
- Coronary heart disease (CHD)

#### Guideline Category

Management  
Prevention  
Risk Assessment  
Screening  
Treatment

#### Clinical Specialty

Cardiology  
Family Practice  
Geriatrics  
Internal Medicine  
Nursing  
Preventive Medicine

#### Intended Users

Advanced Practice Nurses  
Dietitians  
Nurses  
Physician Assistants  
Physicians

#### Guideline Objective(s)

To present recommendations for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) by outlining strategies for lipid screening, identifying patients who would benefit from treatment, and recommending

outlining strategies for lipid screening, identifying patients who would benefit from treatment, and recommending appropriate treatment regimens

### Target Population

Adults 20 to 79 years of age without familial or severe dyslipidemias or chronic kidney disease (CKD)

### Interventions and Practices Considered

1. Screening with fasting/non-fasting baseline lipid profile
2. Assessment of clinical atherosclerotic cardiovascular disease (ASCVD) risk factors
3. Lifestyle modifications (weight loss, exercise, smoking cessation)
4. Statin therapy (non-statin medications in statin-intolerant patients)
5. Treatment of triglycerides  $\geq 500$  mg/dL
6. Referral to specialist in lipid management (if indicated)
7. Long term follow-up/repeat screening

### Major Outcomes Considered

- Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides levels
- Incidence of coronary heart disease (CHD) and stroke, and rate of coronary events
- Total mortality associated with CHD
- Drug interactions and adverse effects

### Methodology

#### Methods Used to Collect/Select the Evidence

Searches of Electronic Databases

#### Description of Methods Used to Collect/Select the Evidence

The literature search for this update began with results of the literature searches performed in 1999 for the 2000 version of this guideline and in 2007 for the 2009 update of this guideline. Since that time the American Association of Clinical Endocrinologists performed a search of relevant literature through early 2011 in developing its guidelines for management of dyslipidemia and prevention of atherosclerosis (see references in the original guideline document). Those results were used for the literature through 12/31/10. For more recent literature, a search similar to those previously performed for this guideline was conducted on Medline prospectively using the overall keywords of: *cholesterol (including hyperlipidemia, lipoproteins, HDL cholesterol), consensus development conferences, practice guidelines, guidelines, outcomes and process assessment (health care); clinical trials, controlled clinical trials, multicenter studies, randomized controlled trials, cohort studies; adults; English language; and published from 1/1/2011 to 4/30/2013*. In addition to the overall terms, for primary prevention a major search term was primary prevention of coronary artery disease with specific topic searches for: screening, pharmacotherapy, diet, exercise, alternative or complementary medicines, and other treatment. In addition to the overall terms, for secondary prevention a major search term was secondary prevention (treatment only) of coronary artery disease, peripheral vascular disease, or cerebral vascular disease/stroke with specific topic searches for pharmacotherapy, diet, exercise, alternative or complementary treatment, and other treatment. An additional search using the overall terms was performed for statins and drug interactions and for individual differences and class effects of statins.

The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.

#### Number of Source Documents

Not stated

#### Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

#### Rating Scheme for the Strength of the Evidence

##### Levels of Evidence

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational trials
- D. Opinion of expert panel

#### Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review

### Description of the Methods Used to Analyze the Evidence

Not stated

### Methods Used to Formulate the Recommendations

Expert Consensus

### Description of Methods Used to Formulate the Recommendations

Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

### Rating Scheme for the Strength of the Recommendations

#### Strength of Recommendation

- I. Generally should be performed
- II. May be reasonable to perform
- III. Generally should not be performed

### Cost Analysis

- Statins are not considered cost effective in the low risk group, but may be cost effective in the intermediate risk group.
- For patients with diabetes and no other atherosclerotic cardiovascular disease (ASCVD) risk factors, statin therapy may reasonably be delayed until age 40 since statin use in this population is only marginally cost effective.
- Ezetimibe should only be considered for patients intolerant to statin, niacin, fibrates, and resins, all of which have better evidence supporting their use and are more cost effective.
- There are arguments concerning age recommendations for lipid screening that there is no evidence that screening or treating young adults has been shown to be of benefit, and given their low absolute risk, would not be cost effective.

### Method of Guideline Validation

Internal Peer Review

### Description of Method of Guideline Validation

Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Family Medicine, General Medicine, and Cardiology. The final version was endorsed by the Clinical Practice Committee of the University of Michigan Faculty Group Practice and the Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers.

## Recommendations

### Major Recommendations

**Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC):** The following guidance was current as of May 2014. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the [original guideline document](#) for the most current version.

**Note from NGC:** The following key points summarize the content of the guideline. Refer to the original guideline document for additional information.

The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the "Major Recommendations" field.

#### Screening/Baseline Lipid Profile

**Patients.** All men age  $\geq 35$  and women age  $>45$  and also men age 20 to 35 and women age 20 to 45 if at increased risk for atherosclerotic cardiovascular disease (ASCVD) [IC]. Can also consider checking baseline lipid profile in adults  $\geq 20$  who are free from ASCVD for assessment of traditional ASCVD risk factors (age, sex, total and high-density lipoprotein cholesterol [HDL-C], systolic blood pressure [BP], use of antihypertensive therapy, diabetes, and current smoker) [IIC].

**Fasting/non-fasting.** Screening test can be obtained fasting or non-fasting to facilitate obtaining data.

#### Assess ASCVD Risk Factors

- Clinical ASCVD (includes stroke; peripheral arterial disease; coronary heart disease [CHD]).
- Low-density lipoprotein cholesterol (LDL-C)  $\geq 190$  mg/dL and age  $\geq 21$ , not caused by drugs or underlying medical condition (see Table 1 in the original guideline document).
- Diabetes mellitus type 1 or 2, age 40 to 75 years of age with LDL-C 70 to 189 mg/dL.
- 10-year ASCVD risk  $\geq 7.5\%$  for ages 40 to 75 years (see Table 2 in the original guideline document for calculation information).

- Chronic kidney disease (CKD) (If CKD, see the NGC summary of the UMHS CKD guideline [Management of chronic kidney disease](#) for managing lipids in CKD patients).
- For additional risk factors to consider, see Table 3 in the original guideline document.

#### **If No ASCVD or None of the Above Risk Factors**

Reinforce healthy lifestyle. Education as appropriate: smoking cessation, diet-exercise-weight loss, reduce excessive alcohol [IA].

Follow-up. Repeat screening/risk assessment in 4 to 6 years [IID]. If borderline, consider repeat in 1 to 2 years.

#### **If ASCVD or Above Risk Factors Other Than CKD**

Treatment through lifestyle changes. Education as appropriate: smoking cessation (reduces coronary event rate by ~50% within 1 to 2 years), diet-exercise-weight loss, reduce excessive alcohol [IA].

Initiate statin therapy. (Non-statin medications should be considered only in statin-intolerant patients.)

- Discuss with patient: risk reduction benefits, adverse effects, drug interactions, patient preferences.
- Check baseline alanine transaminase (ALT) (see Table 4 in the original guideline document for monitoring abnormal baseline ALT for monitoring if liver function tests are abnormal).
- Dosing for LDL-C reduction: high-intensity statin ( $\geq 50\%$ ), moderate-intensity statin (30%-50%). See Tables 5-8 in the original guideline document for "intensity" levels, effects, interactions, and contraindications.
- Four main treatment benefit groups and their dosing intensity:
  - Clinical ASCVD: age  $\leq 75$  years = high-intensity [IA]; age  $> 75$  years = moderate intensity [IID]
  - LDL-C  $\geq 190$  mg/dL, age  $\geq 21$  = high-intensity [IA]
  - Diabetes (type 1 or 2) and age 40 to 75 years with LDL-C 70 to 189 mg/dL = moderate intensity [IA]; can consider high-intensity if 10-year ASCVD risk  $\geq 7.5\%$  [IID]
  - 10-year ASCVD risk  $\geq 7.5\%$  and age 40 to 75 years = moderate-to-high intensity [IA]
  - If other risks (see Table 3 in the original guideline document), consider statin therapy based on individual benefit and harm.
- In 6 to 12 weeks:
  - Check lipids to evaluate adherence. Check ALT only if baseline abnormal, known liver disease, risk factors for liver disease, or on other potentially hepatotoxic medications. Check creatine kinase (CK) only if symptomatic muscle aches/weakness. If statin-intolerance, address (see Table 9 in the original guideline document).
  - If lipids do not decrease as expected: address adherence, reinforce lifestyle modifications, and consider referral to specialist in lipid management.

Triglycerides. After initiating statin therapy, if fasting triglycerides  $\geq 500$  mg/dL, consider treating.

Longer term follow-up. Check lipids annually to assess adherence.

#### **Definitions:**

#### **Levels of Evidence**

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational trials
- D. Opinion of expert panel

#### **Strength of Recommendation**

- I. Generally should be performed
- II. May be reasonable to perform
- III. Generally should not be performed

#### **Clinical Algorithm(s)**

None provided

#### **Evidence Supporting the Recommendations**

##### **Type of Evidence Supporting the Recommendations**

The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.

#### **Benefits/Harms of Implementing the Guideline Recommendations**

##### **Potential Benefits**



Appropriate screening and management of lipids in order to prevent atherosclerotic cardiovascular disease (ASCVD) and stroke

## Potential Harms

- Statins:
  - The most common adverse effect from statins is muscle aches. No evidence indicates that myalgias are more common with one statin than another. Rhabdomyolysis is a life threatening complication of statin therapy, with a 10% mortality rate. The average incidence per 10,000 person-years for monotherapy is 0.44. For patients with known risk factors for rhabdomyolysis, including those with hypothyroidism, chronic renal insufficiency, and those over age 65, who require low-density lipoprotein cholesterol (LDL-C) lowering greater than can be achieved with simvastatin 40 mg, atorvastatin or rosuvastatin may be considered as alternatives (see the original guideline document for information about adverse effects associated with high-dose simvastatin and statin interactions with other medications).
  - The American College of Cardiology/American Heart Association (ACC/AHA) guideline on the treatment of blood cholesterol notes that the main adverse consideration is the excess risk of diabetes – about 0.1 excess case per 100 individuals treated with a moderate-intensity statin for 1 year and about 0.3 excess cases per 100 individuals treated with a high-intensity statin for 1 year. Both statin-treated and placebo-treated participants experienced the same rate of muscle symptoms. The actual rate of statin-related muscle symptoms in the clinical population is unclear.
  - Characteristics predisposing individuals to statin adverse effects include multiple and serious co-morbidities including impaired renal or hepatic function, history of previous statin intolerance or muscle disorders, unexplained alanine transaminase (ALT) elevations >3X upper limit of normal (ULN), or concomitant use of drugs affecting statin metabolism, and age >75 years. If any of these predisposing characteristics are present, moderate-intensity statin therapy is recommended in individuals whom high-intensity statin therapy would otherwise be recommended. High-intensity statin therapy should also be used cautiously in patients of Asian ancestry or with a history of hemorrhagic stroke.
- Adverse effects are common with resins, and are dose dependent. The most common side effects are bloating, nausea, constipation, and abdominal pain. Resins interfere with absorption of fat-soluble vitamins and many drugs.
- Adverse effects of niacin include flushing, pruritus, gastrointestinal (GI) disturbances, fatigue, glucose intolerance, and gout. Hepatic toxicity has been reported, particularly with sustained release products at doses >2 gm/day. Niacin should be avoided in patients with underlying liver disease or uncontrolled diabetes.
- Adverse effects of fibrates are generally GI, including nausea, dyspepsia, and change in bowel habits. The risk of cholestasis and cholecystectomy is increased. Fibrates carry a small risk of myopathy as monotherapy, but the risk is increased markedly when gemfibrozil is combined with statins. Fibrates may cause a small reversible increase in creatinine, and dose adjustment in renal insufficiency.
- For patients with known coronary heart disease (CHD), exercise must be tailored to the degree of disease. Aerobic exercises (walking, cycling, swimming) should be done at levels that do not precipitate cardiac ischemia and angina.
- Further information concerning general cautions about drug class and drug interactions are provided in Table 6 and Table 7 in the original guideline document.

## Contraindications

### Contraindications

- Treatment with statins, niacin, and ezetimibe are contraindicated during pregnancy and lactation
- Niacin is contraindicated in hepatic disease.
- Nicotine replacement therapy is contraindicated in unstable angina or acute myocardial infarction (MI).
- Fibrates are contraindicated in severe renal or liver disease, pregnancy, or preexisting gall bladder disease.
- Contraindications and dose limitations for simvastatin and lovastatin are presented in Table 8 in the original guideline document.

## Qualifying Statements

### Qualifying Statements

These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.

## Implementation of the Guideline

### Description of Implementation Strategy

An implementation strategy was not provided.

### Implementation Tools

Patient Resources

Staff Training/Competency Material

For information about availability, see the *Availability of Companion Documents* and *Patient Resources* fields below.

## Institute of Medicine (IOM) National Healthcare Quality Report Categories

### IOM Care Need

- Getting Better
- Staying Healthy

### IOM Domain

- Effectiveness
- Patient-centeredness

## Identifying Information and Availability

### Bibliographic Source(s)

University of Michigan Health System. Screening and management of lipids. Ann Arbor (MI): University of Michigan Health System; 2014 May. 20 p. [20 references]

### Adaptation

Not applicable: The guideline was not adapted from another source.

### Date Released

2000 May (revised 2014 May)

### Guideline Developer(s)

University of Michigan Health System - Academic Institution

### Source(s) of Funding

University of Michigan Health System

### Guideline Committee

Lipid Therapy Guideline Team

### Composition of Group That Authored the Guideline

*Team Leader:* Audrey L Fan, MD, General Medicine

*Team Members:* Jill N Fenske, MD, Family Medicine; R Van Harrison, PhD, Medical Education; Elizabeth A Jackson, MD, Cardiology; Marie A Marcelino, PharmD, Pharmacy

*Ambulatory Clinical Guidelines Oversight:* Grant Greenberg, MD, MA, MHSA; R Van Harrison, PhD

### Financial Disclosures/Conflicts of Interest

The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

Team Member	Company	Relationship
Audrey L Fan	(none)	
Jill N Fenske, MD	(none)	
R Van Harrison, PhD	(none)	
Elizabeth A Jackson, MD	Consultant	Pfizer
Marie A Marcelino, PharmD	(none)	

### Guideline Status

This is the current release of the guideline.

The guideline updates a previous version: University of Michigan Health System. Screening and management of lipids. Ann Arbor (MI): University of Michigan Health System; 2009 Feb. 15 p. [12 references]

### Guideline Availability

Electronic copies: Available from the [University of Michigan Health System Web site](#).

### Availability of Companion Documents

Continuing Medical Education (CME) information is available from the [University of Michigan Health System Web site](#).

## Patient Resources

The following is available:

- What you need to know about high blood cholesterol. Ann Arbor (MI): University of Michigan Health System; 2014 May 1. 5 p. Electronic copies: Available from the [University of Michigan Health System \(UMHS\) Web site](#) .

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

## NGC Status

This NGC summary was completed by ECRI on January 26, 2001. The information was verified by the guideline developer on March 12, 2001. This summary was updated on September 6, 2001 following the withdrawal of the drug Baycol (Cerivastatin). This summary was updated again on January 19, 2004. The information was verified by the guideline developer on February 6, 2004. This summary was updated by ECRI Institute on July 13, 2009. The updated information was verified by the guideline developer on July 21, 2009. This summary was updated by ECRI Institute on June 27, 2011 following the U.S. Food and Drug Administration advisory on Zocor (simvastatin). This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs. This summary was updated by ECRI Institute on September 11, 2014.

## Copyright Statement

This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).

## Disclaimer

### NGC Disclaimer

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion-criteria.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.